semaglutide
Indication: Obesity (BMI ≥30) and overweight (BMI ≥27) with weight-related comorbidity; Type 2 Diabetes
Interactive semaglutide (Wegovy®/Ozempic®) population PK/PD simulator predicting individual weight loss over 68 weeks by dose escalation schedule, body weight, sex, T2D status, HbA1c, and age. Based on Strathe et al. 2023 STEP trials model (n=2,580).
Drug Overview
Clinical Context
- Molecular Target
- GLP-1 Receptor
- Drug Class
- GLP-1 Receptor Agonist
- Therapeutic Area
- Obesity / Weight Management
- Indication
- Obesity (BMI ≥30) and overweight (BMI ≥27) with weight-related comorbidity; Type 2 Diabetes
- Route of Administration
- Subcutaneous
Model Information
- Model Type
- Population PK/PD (1-CMT + Emax/Indirect Response)
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| ka | 0.018 |
PD Parameters
| Parameter | Value |
|---|---|
| EC50 | 0.98 |
Additional Parameters
| Parameter | Value |
|---|---|
| V/F | 12.5 |
| CL/F | 0.064 |
| t1/2 | 135 |
| Emax (direct) | -7.2 |
| Emax (indirect) | -14.8 |
| T2D effect on Emax | 0.68 |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for semaglutide allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK/PD (1-CMT + Emax/Indirect Response) model characterizes the pharmacokinetics of this glp-1 receptor agonist following subcutaneous administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the semaglutide PK simulator?
This is a free, interactive pharmacokinetic simulator for semaglutide used in Obesity (BMI ≥30) and overweight (BMI ≥27) with weight-related comorbidity; Type 2 Diabetes. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does semaglutide belong to?
semaglutide is classified as a GLP-1 Receptor Agonist that targets GLP-1 Receptor. It is used in the Obesity / Weight Management therapeutic area.
What route of administration does this model simulate?
This simulator models Subcutaneous administration of semaglutide. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK/PD (1-CMT + Emax/Indirect Response) model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Ready to Simulate?
Launch the semaglutide simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community